International Center for Ethnobotanical Education, Research & Service (ICEERS), Barcelona, Spain.
85 papers in the library · 4,276 citations · publishing 0-2026
Natural product research May 1, 2023 Genís Ona, Maja Kohek, José Carlos Bouso 2 citations
The authors argue that the emerging field of psychedelic research can benefit from natural product research. They outline specific research topics involving hallucinogens that directly connect with broader natural product research.
PLOS mental health January 1, 2025 Óscar Andión, José Carlos Bouso, Jerome J Sarris et al. 1 citation
Ayahuasca, a traditional Amazonian decoction, is being studied for mental health benefits, but its adverse effects are not well understood. An analysis of 10,836 participants from the Global Ayahuasca Survey found that 14.2% had a prior anxiety disorder and 19.7% a depressive disorder, yet their median mental health score (SF-12) was 50.16, comparable to the general population. A history of anxiety or depression was linked to more adverse mental states after use. However, experiences like visual distortions and higher ayahuasca use correlated with better mental health. Women reported more adverse states but no worsened mental health.
Journal of psychopharmacology (Oxford, England) May 31, 2026 Anna Beatriz Vicentini, Caio César De Paula, José Augusto Silva Reis et al.
A systematic review of 48 studies (14 experimental, 34 observational) covering 2016–2024 found that classic psychedelics—such as psilocybin and ayahuasca—most consistently increase the personality trait Openness and reduce Neuroticism. Changes in Extraversion, Agreeableness, and Conscientiousness were more variable. Microdosing was linked to modest reductions in Neuroticism and higher Absorption. Most studies used the Five-Factor Model. The findings suggest psychedelics can promote lasting personality changes, but contradictory results remain, and future research should combine experimental and naturalistic designs with longer follow-ups.
Psychedelics April 20, 2026 José Carlos Bouso, Óscar Andión, Jordi Cantillo et al.
A 12-month study of 264 Western participants who attended Shipibo-led ayahuasca retreats in the Peruvian Amazon found lasting psychological improvements. Neuroticism and Openness to Experience decreased, while Extraversion increased. Quality of life improved across all measured domains, and decentering capacities increased with moderate to high effect sizes. Most participants (91.7%) reported long-term benefits, primarily in spiritual well-being, mental health, and personal growth. Adverse effects were minimal (2.3%). Higher baseline psychological distress was associated with higher Neuroticism and lower decentering, suggesting that enhancing decentering may serve as a resilience factor. The findings support ethical, non-extractive integration of traditional Amazonian practices into global mental health frameworks.
Journal of psychopharmacology (Oxford, England) March 9, 2026 Caio César De Paula, Anna Beatriz Vicentini, Lorena Terene Lopes Guerra et al.
A systematic review of 16 studies found that ayahuasca has distinct short- and long-term cognitive effects. In the short term, improvements in working memory and cognitive flexibility were observed, linked to neurochemical modulation of cortical networks. Observational studies reported increased empathy and emotion recognition, while experimental studies only found reduced reaction times in social cognition tasks. Long-term studies generally found no neuropsychological deficits, with some reporting improved memory and executive function. The review notes methodological limitations including small sample sizes, varied protocols, and potential learning effects, calling for more controlled, randomized studies.
European Neuropsychopharmacology February 12, 2026 José Carlos Bouso, Óscar Andión, Sabela Fondevila Estévez et al.
Regular users of ayahuasca or cannabis show no detectable lasting impairments in executive function or working memory compared to non-users, after abstaining for 10-30 days. Personality traits, not cognition or psychopathology, best distinguish the groups: ayahuasca users score higher on self-transcendence and lower on harm avoidance and persistence, while cannabis users score higher on novelty seeking and impulsive nonconformity and lower on introvertive anhedonia. Although ayahuasca users had a higher lifetime prevalence of mood and anxiety disorders, they showed no current psychopathological symptoms. The study's cross-sectional, self-selected, non-treatment-seeking sample may limit generalizability.
PLoS ONE October 13, 2025 Francisco González-espejito, Laura Esteban Rodríguez, Eduardo J. Pedrero Pérez et al.
Ibogaine, a compound from the iboga plant used in traditional Bwiti rituals, shows promise for treating opioid dependence and neurological conditions, but existing tools fail to capture its dream-like subjective effects. A new 70-item Ibogaine Experience Scale (IES) was developed from a prior qualitative study and tested with 499 participants in neuropsychiatric and substance use treatment settings. The final scale has seven factors—including narrative visions, visual changes, discomfort, cosmic visions, introspection, somatosensory sensitivity, and dissociation—explaining 53.9% of variance, with excellent statistical fit and high internal consistency. The IES offers a reliable way to measure ibogaine's multidimensional effects for research and clinical use.
Psychoactives July 15, 2025 Bianca Villanova, Giordano Novak Rossi, Lorena Terene Lopes Guerra et al.
Ayahuasca, a psychoactive brew containing DMT and harmine, may reduce pain and inflammation. A systematic review of 29 preclinical studies found that ayahuasca and its alkaloids, especially harmine, produce antinociceptive effects and shift cytokine balance toward anti-inflammatory. More research is needed.
Frontiers in psychiatry January 1, 2025 Jonathan David, José Carlos Bouso, Maja Kohek et al. correction
A correction was issued for a published article: the average number of ayahuasca uses in the ayahuasca group was revised from 69.4 to 55.7 (standard deviation 82.1). Participants had used ayahuasca 5.2 times more than psilocybin, 4.6 times more than mescaline, and 5.6 times more than LSD. The authors state the error does not alter the scientific conclusions.
Archives of Pharmacology and Therapeutics January 1, 2024 Débora González, Jordi Cantillo, José Carlos Bouso
Grief is a universal and recurrent experience, as each of the approximately 58 million annual deaths worldwide directly affects about nine close relatives. This underscores that bereavement is not a one-time event but a process that can occur multiple times across a person's life.